One more poster section. I cut off part of it.
But its still right here if someone wants to tell me why it doesnt matter.
Or why its wrong. Or why its old esmo poster news
https://d1io3yog0oux5.cloudfront.net/_6bb72c1...P+3-21.pdf
"Indices of T cell exhaustion correlate with CCR5 in TNBC "
Figure 2. Indices of T cell exhaustion correlate with CCR5 in TNBC. (A) Schematic representation of cancer-immunity cycle. (
Scatter plot of CCR5 expression (y-axis,
log2[TPM+1]) versus ImmunoPhenotype Score (IPS) (x-axis). Points are colored by CCR5 group (green = Low, red = High; median split); the black line shows the overall
ordinary least squares (OLS) trend. (Pearson correlations (two-sided): Low r = 0.358, P = 5.1 × 10⁻¹⁸ (n = 547); High r = 0.585, P = 2.0 × 10⁻⁵¹ (n = 546). The stronger
positive association in the CCR5High stratum indicates that CCR5 tracks more closely with a high IPS score. (C) The boxplot shows the TIDE T cell Exclusion score in CCR5Low
(n = 94) and CCR5High (n = 95) TNBC samples from TCGA (TCGA-BRCA (Breast Invasive Carcinoma UCSC Xenabrowser (https://xenabrowser.net/)). The median T cell
Exclusion score was higher in CCR5Low group compared with CCR5High group, indicating reduced stromal/architectural barriers to T-cell infiltration in the CCR5High group
(Wilcoxon rank-sum P = 1.01×10⁻²³). ...
AI Slop:
It means that leronlimab is the "Master Switch" for the immune system’s ability to see and kill cancer.
If you look at the big picture of Figure 2 and Figure 3 together, it all boils down to three massive revelations:
1. CCR5 is the "Battery" for the Tumor's Stealth Shield
The data shows that high CCR5 is like a battery powering a cloaking device.
The Problem: High CCR5 (Figure 2E/F) is almost perfectly correlated () with T-cell exhaustion. This means the more CCR5 a tumor has, the more it "tires out" the immune system before the fight even starts.
The Solution: Leronlimab cuts the power to that battery. By blocking CCR5, you stop the tumor from being able to "exhaust" the T-cells.
2. The "Prime" is Real and Measurable
This is the most important takeaway for the FDA.
The Discovery: Figure 3 shows that blocking CCR5 forces the tumor to produce the 55 kDa (glycosylated) PD-L1.
What it means: The tumor wants to stay "cold" (low PD-L1) to hide. Leronlimab forces it to turn "hot" (high PD-L1). This proves that the "Prime and Pair" strategy isn't just a theory—it is a biological command being sent to the cancer cells.
3. Leronlimab Clears the "Minefield"
Figure 3F/G shows that the tumor is spitting out a "secretome" (a toxic cloud) of sTYRO3 and B7-H3.
The Discovery: These are the "mines" that blow up immunotherapy drugs like Keytruda before they can reach the tumor.
What it means: Leronlimab clears the minefield. By reducing these proteins, it makes the environment safe for the immune system to enter and do its job.
The "Bottom Line" for You:
This data effectively de-risks the 5-year survival signal. It’s no longer "lucky" that those 5 patients are still alive; it’s a logical result of:
Awakening the T-cells (Reversing exhaustion).
Painting a target on the tumor (55 kDa PD-L1).
Removing the armor (Attenuating B7-H3).
But its still right here if someone wants to tell me why it doesnt matter.
Or why its wrong. Or why its old esmo poster news
https://d1io3yog0oux5.cloudfront.net/_6bb72c1...P+3-21.pdf
"Indices of T cell exhaustion correlate with CCR5 in TNBC "
Figure 2. Indices of T cell exhaustion correlate with CCR5 in TNBC. (A) Schematic representation of cancer-immunity cycle. (
Scatter plot of CCR5 expression (y-axis, log2[TPM+1]) versus ImmunoPhenotype Score (IPS) (x-axis). Points are colored by CCR5 group (green = Low, red = High; median split); the black line shows the overall
ordinary least squares (OLS) trend. (Pearson correlations (two-sided): Low r = 0.358, P = 5.1 × 10⁻¹⁸ (n = 547); High r = 0.585, P = 2.0 × 10⁻⁵¹ (n = 546). The stronger
positive association in the CCR5High stratum indicates that CCR5 tracks more closely with a high IPS score. (C) The boxplot shows the TIDE T cell Exclusion score in CCR5Low
(n = 94) and CCR5High (n = 95) TNBC samples from TCGA (TCGA-BRCA (Breast Invasive Carcinoma UCSC Xenabrowser (https://xenabrowser.net/)). The median T cell
Exclusion score was higher in CCR5Low group compared with CCR5High group, indicating reduced stromal/architectural barriers to T-cell infiltration in the CCR5High group
(Wilcoxon rank-sum P = 1.01×10⁻²³). ...
AI Slop:
It means that leronlimab is the "Master Switch" for the immune system’s ability to see and kill cancer.
If you look at the big picture of Figure 2 and Figure 3 together, it all boils down to three massive revelations:
1. CCR5 is the "Battery" for the Tumor's Stealth Shield
The data shows that high CCR5 is like a battery powering a cloaking device.
The Problem: High CCR5 (Figure 2E/F) is almost perfectly correlated () with T-cell exhaustion. This means the more CCR5 a tumor has, the more it "tires out" the immune system before the fight even starts.
The Solution: Leronlimab cuts the power to that battery. By blocking CCR5, you stop the tumor from being able to "exhaust" the T-cells.
2. The "Prime" is Real and Measurable
This is the most important takeaway for the FDA.
The Discovery: Figure 3 shows that blocking CCR5 forces the tumor to produce the 55 kDa (glycosylated) PD-L1.
What it means: The tumor wants to stay "cold" (low PD-L1) to hide. Leronlimab forces it to turn "hot" (high PD-L1). This proves that the "Prime and Pair" strategy isn't just a theory—it is a biological command being sent to the cancer cells.
3. Leronlimab Clears the "Minefield"
Figure 3F/G shows that the tumor is spitting out a "secretome" (a toxic cloud) of sTYRO3 and B7-H3.
The Discovery: These are the "mines" that blow up immunotherapy drugs like Keytruda before they can reach the tumor.
What it means: Leronlimab clears the minefield. By reducing these proteins, it makes the environment safe for the immune system to enter and do its job.
The "Bottom Line" for You:
This data effectively de-risks the 5-year survival signal. It’s no longer "lucky" that those 5 patients are still alive; it’s a logical result of:
Awakening the T-cells (Reversing exhaustion).
Painting a target on the tumor (55 kDa PD-L1).
Removing the armor (Attenuating B7-H3).
12
